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INTRODUCTION
Coats’ disease was first reported in 1908 (1), and it is a nonhere-
ditary disease characterized by idiopathic retinal telangiectasia,
intraretinal and subretinal exudation, and exudative retinal detach-
ment. There is no sign of inflammation. In addition, there may be
capillary nonperfusion, aneurysmal formation, and massive lipid
deposition (2). Degeneration of the endothelial and mural cells of
the retinal arteries and veins has been suggested to be the pri-
mary pathologic defect of this disease, and the changes can result
in dilation and convolution of the retinal vessels leading to exuda-
tion (3). Light and electron microscopic examinations of the retina
of younger Coats’ disease patients reveal a loss of endothelial cells
and pericytes of the affected vessels with mural disorganization and
breakdown of the blood-retinal barrier (4). Coats’ disease usually
occurs unilaterally in young men and, if untreated, can lead to total
retinal detachment and secondary glaucoma, sometimes requiring
enucleation (5).
Observation is generally recommended in the earlier stages of
Coats’ disease (5). In cases with a progression to retinal telangi-
ectasia and secondary subretinal exudates, laser photocoagulation
and/or cryoretinopexy are recommended. Patients at an advanced
stage are managed by pars plana vitrectomy, subretinal fluid drain-
age, and silicone oil tamponade (6-9). However, the prognosis is
usually not good (10).
Coats’ disease less commonly presents in later childhood with
similar features. If Coats’ disease is diagnosed in older children,
the condition usually progresses at a slower rate (11). Several stud-
ies have shown that the earlier the age of presentation, the more
severe will be the progression of the disease and the greater the
likelihood of eventual enucleation (5, 11, 12). Smithen et al. (11)
reported that the characteristics of older patients with adult -onset
Coats’ disease included a limited area of involvement, slower pro-
gression, and hemorrhages near the larger vascular dilatations.
None of the patients progressed to the end-stage of Coats’ disease
with iris neovascularization and total exudative retinal detachment.
An epiretinal membrane (ERM) was present in 2 of the 13 cases
adult -onset Coats’ disease presented by Smithen et al. (11), al-
though the details and the management of the ERM were not
presented.
Usually, an ERM develops iatrogenically, e.g., after excess reti-
nal photocoagulation or cryoretinopexy (10, 13). Appiah et al. (13)
studied 187 consecutive patients with a diagnosis of secondary
ERM, and reported that the surgical causes were cataract extrac-
tion in 41.7%, scleral buckle in 18.9%, laser photocoagulation in
9.7%, and cryoretinopexy in 8.0%. In the same way, an ERM is de-
tected after laser photocoagulation and/or cryoretinopexy in eyes
with Coats’ disease. In a case series of 150 patients with juvenile
or adult -onset Coats’ disease, 2 of 79 eyes (2.5%) with a final deci-
mal visual acuity of0.1 had an ERM suggesting that ERM is rare
but can cause severe decrease of the visual acuity (5). Rishi et al.
(14) reported the clinical features, treatment, and outcomes in 307
eyes with Coats’ disease. They reported that an ERM was a com-
plication after treatment in 13 of the 307 eyes (4.4%). However,
there was no mention of any treatment of the secondary ERM in
the above-mentioned 2 large case series (5, 14). Yadav et al. (15)
reported a case that had vitrectomy for an ERM secondary to treat-
ment of juvenile Coats’ disease. In their case, the foveal contour
improved and the vision improved from 0.17 to 1.0 after surgery
indicating excellent surgical outcome.
In cases of untreated Coats’ disease, only several cases of an
ERM have been published (3, 10, 11, 16). To date, only two cases
of juvenile (3) or adult -onset (16) untreated Coats’ disease that
underwent vitrectomy for ERM have been published, and the sur-
gical outcomes were good.
We report a case of adult -onset Coats’ disease with an ERM
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without prior treatment which was successfully treated with 25-
gauge pars plana vitrectomy (25GPPV).
CASE REPORT
A 26-year-old man presented with a 3-week history of reduced
vision in his left eye. There was no history of radiation treatment,
ocular trauma, inflammation, or systemic disease. At the initial visit,
the decimal best-corrected visual acuity (BCVA) was 1.5 in the
right eye and 0.7 in the left eye. The intraocular pressure was 18
mmHg in the right eye and 17 mmHg in the left eye. The anterior
segment of both eyes and fundus of the right eye were normal.
Fundus examination of the left eye showed retinal telangiectasia
with retinal and preretinal hemorrhage, subretinal fluid, and yellow
lipid exudation in the inferotemporal quadrant indicating Stage 2A
(telangiectasia and extrafoveal exudation) Coats’ disease (Figure
1a) (5). The proliferative ERM extended from the inferior margin
of the optic disc to the inferotemporal mid-periphery. A shallow
incomplete posterior vitreous detachment (PVD) was detected.
Fluorescein angiography revealed intense leakage from the periph-
eral telangiectasia (Figure 1b) and aneurysmal dilatations with
adjacent capillary non-perfusion. There were no signs of macular
telangiectasia. Spectral -domain optical coherence tomography (SD-
OCT) showed that the ERM was causing traction on the disc mar-
gin (Figure 1c). A diagnosis of stage 2A Coats’ disease accompa-
nied by a proliferative ERM was made. The patient had not been
treated before our examinations indicating that the ERM was not
due to prior procedures.
The patient received 2 monthly intravitreal injections of 2.5 mg
bevacizumab, 5 laser photocoagulations to the area of the telangi-
ectasia, and 1 session of cryoretinopexy. Four months after the
initial visit, SD-OCT showed an increase in the traction on the disc
margin and slight cystic macular edema (Figure 2a-c). The SD-
OCT images also showed a flattening of the foveal contour. Inferior
dislocation of macula in addition to a flattened foveal contour and
cystic macular edema suggested possible macular involvement.
However, the BCVA remained 0.7. The external limiting mem-
brane and photoreceptor inner/outer segment junction lines were
continuous, although the reflectivities of these lines were slightly
reduced.
Nine month after the initial visit, traction on the parafoveal area
developed causing moderate cystoid macular edema, and the BCVA
decreased to 0.3 (Figure 2d-f). There was an ERM superior to the
fovea, which was not seen 4 months after the initial visit, suggesting
that the ERM might progress after intravitreal bevacizumab, laser
photocoagulation and cryoretinopexy. Two weeks later, he under-
went 25GPPV with the removal of the ERM and air tamponade of
the retina. Intraoperatively, the peripheral telangiectasia was treated
by both laser photocoagulation and cryoretinopexy. No intraocular
dye was used to stain the ERM. Intentional internal limiting mem-
brane (ILM) peeling was not performed during the surgery. Thir-
teen months after the 25GPPV, the traction on the parafoveal area
was not present, and the BCVA improved to 0.6 (Figure 2g- i).
However, macular edema and fine folds of the retinal surface re-
mained, and a small ERM regrowth developed in the region of the
superior arcade vessels. The BCVA remained stable during the
13 months of follow-up after the surgery.
Figure 1. Fundus photograph, fluorescein angiogram, and spectral -domain optical coherence tomographic (SD-OCT) images of an eye with
Coats’ disease at the initial visit. The best -corrected visual acuity was 0.7.
a : Fundus photograph showing retinal telangiectasia inferotemporally with yellow lipid exudation. Retinal and preretinal hemorrhage maybe along
with partial vitreous detachment is observed. An epiretinal membrane (ERM) can be seen extending from the inferior margin of the optic disc to
the inferotemporal midperiphery.
b : Fluorescein angiogram showing intense leakage from the peripheral telangiectasia. There were no signs of macular telangiectasia.
c : SD-OCT image of a horizontal scan through the fovea shows an ERM causing traction on the disc margin.
d : SD-OCT image of a vertical scan through the fovea shows an almost normal foveal contour.
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DISCUSSION
Smithen et al. (11) reported that 7 of 13 patients (53.5%) with
adult -onset Coats’ disease had a final visual acuity of 0.3 or worse,
and that 5 of 13 patients (38.5%) had visual acuity of 0.1 or worse.
Although an ERM was noted in only 2.5 to 4.4% of eyes with Coats’
disease in two earlier studies (5, 14), it is one of the major causes
of visual acuity reduction in older patients. Smithen et al. (11) re-
ported that an ERM was present in 2 of their 13 cases with adult -
onset Coats’ disease diagnosed after age 35 years (mean age of
the 13 patients was 50 years). We suggest that Coats’ disease com-
plicated by an ERM is even rarer if the patient is in the 20’s as in
our case.
Inoue et al. (17) performed vitrectomy on 4 patients with juvenile
Coats’ disease with exudative detachment, and none had a com-
plete PVD preoperatively. Wolfensberger et al. (3) reported that
an ERM usually developed after a PVD had developed in the ma-
jority of patients with adult -onset Coats’ disease. In our case with
adult -onset Coats’ disease, a PVD was detected at the initial visit.
The pathogenesis of the ERM in Coats’ disease has not been
conclusively determined, but Machemer (18) suggested that a
chronic leakage from diseased vessels leads to reactive glial pro-
liferation on the retinal surface. The development of ERM then
causes traction on the retina and further accumulation of subretinal
fluid.
To date, only two cases of untreated juvenile (3) or adult -onset
(16) Coats’ disease that underwent vitrectomy for an ERM have
been reported. Wolfensberger et al. (3) reported a case of juvenile
Coats’ disease with an ERM which continued to contract after laser
photocoagulation. Then, vitrectomy led to an improvement of the
BCVA from 0.1 to 0.5. Shukla et al. (16) reported that vitrectomy
led to excellent anatomical and functional outcomes in adult -onset
Coats’ disease with an ERM if vitrectomy was performed before
macular exudation and subretinal fibrosis developed. In their cases,
the BCVA improved from 0.17 to 1.0 after vitrectomy with laser
photocoagulation and peeling of the ERM and ILM. They empha-
sized that early vitrectomy and simultaneous endophotocoagulation
is necessary for Coats’ disease with an ERM before submacular
exudation and subsequent submacular fibrosis developed.
In our case, the traction on the parafoveal area was released
and the BCVA improved to 0.6 after the vitrectomy. However, the
macular edema and fine folds of the retinal surface remained, and
the BCVA did not change during the 13 months follow-up period.
There is a possibility of better visual outcome, if vitectomy had
been performed 4 months after the initial visit when an increase
in the traction on the disc margin was first detected.
On the other hand, Lafaut et al. (19) and Sugimoto et al. (10)
reported cases of Coats’ disease with spontaneous peeling of the
ERM after laser photocoagulation. Both groups suggested that
the PVD induced by laser photocoagulation led to the peeling of
the ERM which was attached firmly to the posterior vitreous mem-
brane. In fact, Sugimoto et al. (10) observed that a PVD developed
after laser photocoagulation, and that the ERM detached from the
vitreous concomitantly with the development of the PVD. Because
the ERM was too firmly attached and wide spread in our case, a
spontaneous peeling would not be expected.
Figure 2. Fundus photographs and spectral -domain optical coherence tomographic (SD-OCT) images after treatment. (a, d, g) Fundus photo-
graphs. (b, e, h) SD-OCT images of a horizontal scan through the fovea. (c, f, i) SD-OCT images of a vertical scan through the fovea. There was
no symptom of metamorphopsia or diplopia before surgery.
a -c : Four months after the initial visit, SD-OCT shows stronger traction on the disc margin and slight cystic changes after treatment with in-
travitreal bevacizumab injections, laser photocoagulations, and cryoretinopexy. Inferior dislocation of macula in addition to a flattened foveal contour
and cystic macular edema suggests possible macular involvement. However, the decimal best -corrected visual acuity (BCVA) remained 0.7.
d - f : Nine months after the initial visit, traction to the parafoveal area is present causing moderate cystoid macular edema, and the BCVA decreased
to 0.3. There is an epiretinal membrane (ERM) superior to the fovea, which was not seen 4 months after the initial visit (a), suggesting that the ERM
might progress after intravitreal bevacizumab, laser photocoagulation and cryoretinopexy.
g- i : Thirteen months after 25 -gauge pars plana vitrectomy, the traction on the parafoveal area is released and the BCVA has improved to 0.6. Macular
edema and fine folds of the retinal surface remain, and a small regrowth of the ERM is seen at the superior arcade vessel.
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Vascular endothelial growth factor (VEGF) has been identified
as a key regulator of angiogenesis and vascular permeability (20).
Lin et al. (20) reported that the mean intraocular concentration of
VEGF in 4 eyes with Coats’ disease was 2394.5 pg/ml which was
significantly higher than the 15.3 pg/ml in 5 eyes with rhegmatoge-
nous retinal detachment. There have been several reports on the
effect of anti -VEGF therapy with intravitreal bevacizumab alone
or in combined with laser photocoagulation in Coats’ disease.
These treatments benefited Coats’ disease cases with macular
edema and exudative retinal detachment (21-23). However, the
use of anti -VEGF therapy has not been proven to have marked
effect on the visual outcomes (24). For adult -onset Coats’ disease,
Ramasubramanian et al. (22) reported complications such as vitreo-
retinal fibrosis and traction retinal detachment after intravitreal
bevacizumab combined with standard therapy. Similarly, traction
by the ERM was increased after intravitreal bevacizumab, laser
photocoagulations, and cryoretinopexy in our case.
Shienbaum et al. (2) reported on the recurrent nature of Coats’
disease. They followed 12 patients treated for Coats’ disease for
an average follow-up period of 12.4 years. Four of the 12 patients
(33%) had recurrences, and three of the four had multiple recur-
rences. The average elapsed time from successful treatment to
the first recurrence was 4.3 years, and the average number of
recurrences was 3.3. Shukla et al. (16) raised caution about late
recurrences of ERMs many months or years after a successful
vitrectomy for ERM secondary to Coats’ disease. Consistent with
their findings, a small ERM regrowth developed in the superior
arcade vessel 13 months after vitrectomy in our case. No intraop-
erative ILM peeling might contribute to this ERM regrowth.
In conclusion, 25GPPV combined with ERM peeling, laser photo-
coagulation, and cryoretinopexy may be an effective treatment regi-
men for adult -onset Coats’ disease with an ERM. However, the
patients should be examined periodically to detect recurrences.
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